The Experts below are selected from a list of 17994 Experts worldwide ranked by ideXlab platform
Rosario Menendez - One of the best experts on this subject based on the ideXlab platform.
-
Thrombocytosis is a marker of poor outcome in community acquired pneumonia
Chest, 2013Co-Authors: Elena Prina, Miquel Ferrer, Otavio T Ranzani, Eva Polverino, Catia Cilloniz, Encarnacion Moreno, Josep Mensa, Beatriz Montull, Rosario MenendezAbstract:Background Thrombocytosis, often considered a marker of normal inflammatory reaction of infections, has been recently associated with increased mortality in hospitalized patients with community-acquired pneumonia (CAP). We assessed the characteristics and outcomes of patients with CAP and Thrombocytosis (platelet count ≥ 4 × 10 5 /mm 3 ) compared with thrombocytopenia (platelet count 5 /mm 3 ) and normal platelet count. Methods We prospectively analyzed 2,423 consecutive, hospitalized patients with CAP. We excluded patients with immunosuppression, neoplasm, active TB, or hematologic disease. Results Fifty-three patients (2%) presented with thrombocytopenia, 204 (8%) with Thrombocytosis, and 2,166 (90%) had normal platelet counts. Patients with Thrombocytosis were younger ( P P P P P = .009), need for invasive mechanical ventilation ( P P = .011). Patients with Thrombocytosis and patients with thrombocytopenia had longer hospital stays ( P = .004), and higher 30-day mortality ( P = .001) and readmission rates ( P = .011) than those with normal platelet counts. Multivariate analysis confirmed a significant association between Thrombocytosis and 30-day mortality (OR, 2.720; 95% CI, 1.589-4.657; P P = .049). Conclusions Thrombocytosis in patients with CAP is associated with poor outcome, complicated pleural effusion, and empyema. The presence of Thrombocytosis in CAP should encourage ruling out respiratory complication and could be considered for severity evaluation.
-
Thrombocytosis is a marker of poor outcome in community acquired pneumonia
European Respiratory Journal, 2012Co-Authors: Elena Prina, Miquel Ferrer, Otavio T Ranzani, Eva Polverino, Catia Cilloniz, Encarnacion Moreno, Josep Mensa, Beatriz Montull, Rosario MenendezAbstract:Background: Thrombocytosis, often considered a marker of normal inflammatory reaction of infections, has recently been associated with increased mortality in community-acquired pneumonia (CAP). Methods: We evaluated 2,423 hospitalized patients with CAP. We excluded patients with immunosuppression, neoplasm, tuberculosis or haematological disease. The aim was to assess characteristics and outcomes of patients with CAP and Thrombocytosis (platelet count ≥4x10 5 /mm 3 ), compared with thrombocytopenia(platelet count 5 /mm 3 ) and normal platelet count. Results: Fifty-three patients (2%) presented thrombocytopenia, 204 (8%) Thrombocytosis and 2,166 (90%) a normal platelet count. Patients with Thrombocytosis were younger (p Conclusions: Thrombocytosis in CAP is associated with poor outcome, complicated pleural effusion/empyema. Therefore Thrombocytosis in CAP should encourage to rule out respiratory complications and could be considered for severity evaluation.
Otavio T Ranzani - One of the best experts on this subject based on the ideXlab platform.
-
Thrombocytosis is a marker of poor outcome in community acquired pneumonia
Chest, 2013Co-Authors: Elena Prina, Miquel Ferrer, Otavio T Ranzani, Eva Polverino, Catia Cilloniz, Encarnacion Moreno, Josep Mensa, Beatriz Montull, Rosario MenendezAbstract:Background Thrombocytosis, often considered a marker of normal inflammatory reaction of infections, has been recently associated with increased mortality in hospitalized patients with community-acquired pneumonia (CAP). We assessed the characteristics and outcomes of patients with CAP and Thrombocytosis (platelet count ≥ 4 × 10 5 /mm 3 ) compared with thrombocytopenia (platelet count 5 /mm 3 ) and normal platelet count. Methods We prospectively analyzed 2,423 consecutive, hospitalized patients with CAP. We excluded patients with immunosuppression, neoplasm, active TB, or hematologic disease. Results Fifty-three patients (2%) presented with thrombocytopenia, 204 (8%) with Thrombocytosis, and 2,166 (90%) had normal platelet counts. Patients with Thrombocytosis were younger ( P P P P P = .009), need for invasive mechanical ventilation ( P P = .011). Patients with Thrombocytosis and patients with thrombocytopenia had longer hospital stays ( P = .004), and higher 30-day mortality ( P = .001) and readmission rates ( P = .011) than those with normal platelet counts. Multivariate analysis confirmed a significant association between Thrombocytosis and 30-day mortality (OR, 2.720; 95% CI, 1.589-4.657; P P = .049). Conclusions Thrombocytosis in patients with CAP is associated with poor outcome, complicated pleural effusion, and empyema. The presence of Thrombocytosis in CAP should encourage ruling out respiratory complication and could be considered for severity evaluation.
-
Thrombocytosis is a marker of poor outcome in community acquired pneumonia
European Respiratory Journal, 2012Co-Authors: Elena Prina, Miquel Ferrer, Otavio T Ranzani, Eva Polverino, Catia Cilloniz, Encarnacion Moreno, Josep Mensa, Beatriz Montull, Rosario MenendezAbstract:Background: Thrombocytosis, often considered a marker of normal inflammatory reaction of infections, has recently been associated with increased mortality in community-acquired pneumonia (CAP). Methods: We evaluated 2,423 hospitalized patients with CAP. We excluded patients with immunosuppression, neoplasm, tuberculosis or haematological disease. The aim was to assess characteristics and outcomes of patients with CAP and Thrombocytosis (platelet count ≥4x10 5 /mm 3 ), compared with thrombocytopenia(platelet count 5 /mm 3 ) and normal platelet count. Results: Fifty-three patients (2%) presented thrombocytopenia, 204 (8%) Thrombocytosis and 2,166 (90%) a normal platelet count. Patients with Thrombocytosis were younger (p Conclusions: Thrombocytosis in CAP is associated with poor outcome, complicated pleural effusion/empyema. Therefore Thrombocytosis in CAP should encourage to rule out respiratory complications and could be considered for severity evaluation.
Elena Prina - One of the best experts on this subject based on the ideXlab platform.
-
Thrombocytosis is a marker of poor outcome in community acquired pneumonia
Chest, 2013Co-Authors: Elena Prina, Miquel Ferrer, Otavio T Ranzani, Eva Polverino, Catia Cilloniz, Encarnacion Moreno, Josep Mensa, Beatriz Montull, Rosario MenendezAbstract:Background Thrombocytosis, often considered a marker of normal inflammatory reaction of infections, has been recently associated with increased mortality in hospitalized patients with community-acquired pneumonia (CAP). We assessed the characteristics and outcomes of patients with CAP and Thrombocytosis (platelet count ≥ 4 × 10 5 /mm 3 ) compared with thrombocytopenia (platelet count 5 /mm 3 ) and normal platelet count. Methods We prospectively analyzed 2,423 consecutive, hospitalized patients with CAP. We excluded patients with immunosuppression, neoplasm, active TB, or hematologic disease. Results Fifty-three patients (2%) presented with thrombocytopenia, 204 (8%) with Thrombocytosis, and 2,166 (90%) had normal platelet counts. Patients with Thrombocytosis were younger ( P P P P P = .009), need for invasive mechanical ventilation ( P P = .011). Patients with Thrombocytosis and patients with thrombocytopenia had longer hospital stays ( P = .004), and higher 30-day mortality ( P = .001) and readmission rates ( P = .011) than those with normal platelet counts. Multivariate analysis confirmed a significant association between Thrombocytosis and 30-day mortality (OR, 2.720; 95% CI, 1.589-4.657; P P = .049). Conclusions Thrombocytosis in patients with CAP is associated with poor outcome, complicated pleural effusion, and empyema. The presence of Thrombocytosis in CAP should encourage ruling out respiratory complication and could be considered for severity evaluation.
-
Thrombocytosis is a marker of poor outcome in community acquired pneumonia
European Respiratory Journal, 2012Co-Authors: Elena Prina, Miquel Ferrer, Otavio T Ranzani, Eva Polverino, Catia Cilloniz, Encarnacion Moreno, Josep Mensa, Beatriz Montull, Rosario MenendezAbstract:Background: Thrombocytosis, often considered a marker of normal inflammatory reaction of infections, has recently been associated with increased mortality in community-acquired pneumonia (CAP). Methods: We evaluated 2,423 hospitalized patients with CAP. We excluded patients with immunosuppression, neoplasm, tuberculosis or haematological disease. The aim was to assess characteristics and outcomes of patients with CAP and Thrombocytosis (platelet count ≥4x10 5 /mm 3 ), compared with thrombocytopenia(platelet count 5 /mm 3 ) and normal platelet count. Results: Fifty-three patients (2%) presented thrombocytopenia, 204 (8%) Thrombocytosis and 2,166 (90%) a normal platelet count. Patients with Thrombocytosis were younger (p Conclusions: Thrombocytosis in CAP is associated with poor outcome, complicated pleural effusion/empyema. Therefore Thrombocytosis in CAP should encourage to rule out respiratory complications and could be considered for severity evaluation.
N Milman - One of the best experts on this subject based on the ideXlab platform.
-
prognostic significance of Thrombocytosis in patients with primary lung cancer
European Respiratory Journal, 1996Co-Authors: L M Pedersen, N MilmanAbstract:In patients with malignancies, Thrombocytosis has previously been related to disease stage, histological type, and survival. In the present study, the prevalence of Thrombocytosis and the prognostic information provided by platelet counts were analysed in a large cohort of patients with primary lung cancer. At the time of diagnosis, pretreatment platelet counts were retrospectively recorded in 1,115 consecutive patients with histologically proven primary lung cancer. All patients were reviewed regarding histological type, tumour, node, metastasis (TNM) classification stage and survival. The prevalence of Thrombocytosis in patients with lung cancer was compared with that in a series of 550 consecutive out-patients with benign lung disorders. In 269 surgically resected patients, postoperative platelet counts were recorded 1-3 months after resection of the tumour. In the follow-up period, thromboembolic episodes diagnosed either clinically or at autopsy were recorded. The overall prevalence of Thrombocytosis (> 400 x 10(9) platelets.L-1) in the patients with lung cancer was 32%. The frequency of Thrombocytosis was significantly higher compared with the control subjects (32 vs 6%; p 400 x 10(9) platelets.L-1 greatest in the more advanced TNM stages (stage I and II 23% vs stage III and IV 37%; p < 0.0001). Patients with Thrombocytosis had a significantly poorer survival than patients with normal platelet counts (p < 0.0001). In a multivariate survival analysis (Cox model), Thrombocytosis continued to correlate strongly with poor survival even when adjusted for histological type, sex, age, and TNM stage (p < 0.001). In surgically resected patients, the frequency of preoperative and postoperative Thrombocytosis differed significantly (23.0 vs 8.9%; p < 0.0001). Survival rate was significantly reduced in patients with preoperative Thrombocytosis (p = 0.005). Thrombocytosis was not associated with an increased incidence of thromboembolism. In conclusion, Thrombocytosis is an independent prognostic factor of survival in patients with primary lung cancer. We suggest that platelet counts should be included in future multivariate analyses of survival in patients with lung cancer.
Christoph Tausch - One of the best experts on this subject based on the ideXlab platform.
-
impact of pretreatment Thrombocytosis on survival in primary breast cancer
Thrombosis and Haemostasis, 2003Co-Authors: Susanne Taucher, Andreas Salat, Michael Gnant, Werner Kwasny, Brigitte Mlineritsch, Rainerchristian Menzel, Marianne Schmid, Michael G Smola, M Stierer, Christoph TauschAbstract:Platelet count has been reported to have predictive value in various cancer entities. In the case of breast cancer, evidence about involvement of platelets is still incomplete. Our objective was to assess the influence of pretreatment Thrombocytosis on survival and establish its prognostic relevance for breast cancer patients. We performed a retrospective, multivariate analysis of 4,300 patients with early-stage breast cancer. All subjects participated in one of five prospective, randomized, multicenter trials conducted by the Austrian Breast and Colorectal Cancer Study Group. Thrombocytosis was defined as a platelet count exceeding 400 G/L. Median follow-up was 52 months. Univariate and multiple Cox regression models were calculated for overall survival (OS), breast cancer-related survival and disease-free survival (DFS). Pretreatment Thrombocytosis was observed in 161 patients (3.7%). Estimated median OS, breast cancer-related survival and DFS for patients with versus those without Thrombocytosis was 71.0 versus 99.5, 72.0 versus 100.9, and 80.4 versus 88.4 months, respectively (p = 0.0054, p = 0.0095, p = 0.0199). A multiple Cox regression model including tumor and nodal status, grading, age, hormone receptor status and pretreatment Thrombocytosis identified pretreatment Thrombocytosis as an independent predictive factor for OS (p = 0.0064) and breast cancer-related survival (p = 0.0162). Multivariate analysis failed to identify pretreatment Thrombocytosis as an independent risk factor for DFS (p = 0.1355). In our retrospective study, elevated platelet counts at time of diagnosis were associated with poor prognosis in breast cancer. We hypothesize that platelets may contribute to the pathophysiology of hematogenous metastasis.
